Biofrontera Shares Are Trading Higher After Benchmark Initiates Coverage

Benchmark initiated coverage of Biofrontera Inc $Biofrontera (BFRI.US)$ with a Buy rating and $11 price target.

The Company specializes in medical dermatology, which recently came public in the U.S. as a carve-out from Germany's Biofrontera AG (NASDAQ: BFRA).

Ameluz and Xepi are Biofrontera's current lead products.

Ameluz is poised for "significant growth" given a combination of superior efficacy, attractive reimbursement, and an expanding sales force, writes analyst Bruce Jackson.

Price Action: BFRI shares are up 21.8% at $6.70 during the market session on the last check Wednesday.

Part of the content is taken from Yahoo.